Phase 2, double-blind, multi-center, randomized study comparing tenofovir disoproxil fumarate, emtricitabine/tenofovir disoproxil fumarate, and entecavir in the treatment of chronic hepatitis B subjects with decompensated liver disease and in the prevention of hepatitis B recurrence post-transplantation. [Studio di fase II, multicentrico, randomizzato, in doppio cieco, di confronto fra tenofovir disoproxil fumarato, emtricitabina + tenofovir disoproxil fumarato ed entecavir nel trattamento di soggetti affetti da epatite cronica B con epatopatia scompensata e nella prevenzione della recidiva post-trapianto dell`epatite B]

Trial Profile

Phase 2, double-blind, multi-center, randomized study comparing tenofovir disoproxil fumarate, emtricitabine/tenofovir disoproxil fumarate, and entecavir in the treatment of chronic hepatitis B subjects with decompensated liver disease and in the prevention of hepatitis B recurrence post-transplantation. [Studio di fase II, multicentrico, randomizzato, in doppio cieco, di confronto fra tenofovir disoproxil fumarato, emtricitabina + tenofovir disoproxil fumarato ed entecavir nel trattamento di soggetti affetti da epatite cronica B con epatopatia scompensata e nella prevenzione della recidiva post-trapianto dell`epatite B]

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2013

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate; Entecavir; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 29 Feb 2012 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
    • 23 Feb 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 23 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top